BPC-157: what the published research describes

BPC-157 is one of the most discussed research peptides and one of the least understood. A PubMed search for it returns a little over 200 records, most of the primary studies in rodents, and a large share of them from a single laboratory. This article sets out what the compound is, which experimental models it has been studied in, what those studies describe, who produced the work, and how thin the human record is. Every finding below is tied to the model it came from. None of it should be read as a statement about what the peptide does in people.

What is BPC-157?

BPC-157 is a linear peptide of 15 amino acids, which is why the literature often calls it a pentadecapeptide. Its sequence, written from the N-terminus, is:

Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (one-letter code GEPPPGKPADDAGLV).

Property	Value
Residues	15 (chiral residues in the L form; three consecutive prolines at positions 3–5)
Molecular formula	C62H98N16O22
Molecular weight (average)	about 1419.5 g/mol
Monoisotopic mass	about 1418.70 Da
CAS number	137525-51-0
PubChem CID	9941957
Other names and codes	Bepecin, PL-10, PLD-116, PL 14736

The formula, masses, CAS number and synonyms are from the PubChem compound record. The sequence and the figure of 1419 for the molecular weight also appear in the Zagreb group’s own papers (Sikiric et al., 2006; Staresinic et al., 2003).

The peptide has a net charge close to −2 at neutral pH: the N-terminal amine and one lysine against two aspartic acids, one glutamic acid and the C-terminal carboxyl group. It contains no cysteine, so there are no disulfide bonds to form or check, and no tryptophan or tyrosine, so it absorbs weakly at 280 nm. That last point matters when reading analytical data: purity by HPLC is normally measured at short wavelengths (around 214–220 nm), where the peptide bonds absorb.

For anyone sourcing the peptide for laboratory work, whether from the EuroPeps research-peptide catalogue or another supplier, the values in the table are the reference points a batch certificate should match: an observed mass consistent with 1418.70 Da (monoisotopic) or 1419.5 Da (average), and a stated sequence identical to the one above.

Where does the name “body protection compound” come from?

In 1993, pharmacologists at the University of Zagreb described a protein they had isolated from gastric juice, with a relative molecular mass of about 40,000, and named it BPC, for body protection compound. In the same paper they described a 15-amino-acid fragment, designated BPC 157, which they considered essential to the parent protein’s activity, and set it inside a broader hypothesis about the stomach’s role in the response to stress, which they called “organoprotection” (Sikirić et al., 1993).

Two points about this origin are worth keeping in view. First, the material used in nearly all later work is the synthetic 15-mer, not the parent protein. Second, the larger gastric protein itself has received very little independent characterisation in the indexed literature since that first description.

The group’s later papers use the name stable gastric pentadecapeptide BPC 157. The word “stable” refers to their report that the peptide is unusually resistant to breakdown in gastric juice (Sikiric et al., 2006). That is a claim about stability in that environment, and it should not be confused with a long half-life in the body (see the pharmacokinetics section below).

Which research models has BPC-157 been studied in?

The published work falls into a few broad groups. Almost all of it is in rats, with some mice, a small number of studies in other species, and a body of cell-culture work.

Gastrointestinal models in rodents

The earliest and largest group of studies concerns the rat gastrointestinal tract: lesions of the stomach, oesophagus and duodenum produced with alcohol, NSAIDs or stress, models of colitis, fistulas and surgical anastomoses. In one model reviewed by the Zagreb group, absolute alcohol was instilled into a fully distended rat stomach; in rats that received BPC-157, the visible serosal blood vessels were described as remaining intact and the gastric, oesophageal and duodenal lesions as smaller than in controls (Sikiric et al., 2006). The same review describes interactions with the nitric oxide (NO) system and with dopamine-related models, themes that recur across the group’s work.

Tendon and muscle models in rats

A second group of studies uses surgical injury models of the musculoskeletal system. In a rat model in which the Achilles tendon was transected 5 mm above its insertion, animals given BPC-157 were reported to show higher load to failure and Young’s modulus, higher Achilles functional index scores, and smaller tendon defects than saline controls, assessed at intervals up to 14 days (Staresinic et al., 2003). In the same paper, cultured tendocytes exposed to BPC-157 alone did not grow faster, but the peptide counteracted the growth-inhibiting effect of 4-hydroxynonenal in culture.

A similar design was applied to the rat quadriceps muscle, transected 1 cm above the patella. Over a 72-day observation period the authors reported higher load to failure, better scores on walking and motor-function indices, and histological signs of muscle fibre continuity across the defect in the BPC-157 group (Staresinic et al., 2006).

Cell and explant studies

Mechanistic work has mostly been done in cultured cells. Using rat Achilles tendon explants and the fibroblasts that grow out of them, a group at Chang Gung University in Taiwan reported that BPC-157 sped up fibroblast outgrowth from the explants, did not change fibroblast proliferation in an MTT assay, was associated with higher cell survival under hydrogen peroxide stress, and promoted fibroblast migration and spreading. They linked these observations to dose-dependent phosphorylation of focal adhesion kinase (FAK) and paxillin (Chang et al., 2011).

Blood-vessel models

The same Taiwanese group studied angiogenesis. In the chick chorioallantoic membrane assay and an endothelial tube-formation assay, BPC-157 was associated with higher vessel density. In a rat hind-limb ischaemia model, blood flow measured by laser Doppler returned faster and vessel counts higher in the BPC-157 group. In cultured human vascular endothelial cells, the peptide raised expression of vascular endothelial growth factor receptor 2 (VEGFR2), but not of VEGF-A itself, and activated the VEGFR2–Akt–eNOS signalling pathway; blocking endocytosis with dynasore suppressed these responses (Hsieh et al., 2017).

Central nervous system models

The Zagreb group has also published a series of rat studies in neurological and behavioural models, summarised in a 2022 review: stroke induced by clamping both common carotid arteries followed by reperfusion, catalepsy induced by L-NAME or haloperidol, amphetamine-, apomorphine- and MK-801-based models used to study schizophrenia-like behaviour, and spinal cord compression. In each case the review reports that outcome measures in BPC-157 groups were closer to those of uninjured animals (Vukojevic et al., 2022). These are rodent behavioural and histological endpoints, and most come from a single laboratory.

What has been reported about toxicology and pharmacokinetics?

Two papers from a research group in Xi’an, China, which had developed its own solid-phase synthesis of BPC-157, address questions that the earlier literature largely left open.

The first is a preclinical toxicology package in mice, rats, rabbits and dogs, covering single-dose and repeated-dose toxicity, local tolerance, genotoxicity and embryo-fetal toxicity. The authors reported no serious toxicity in these tests. The one exception they note is a fall in creatinine in dogs at the highest exposure level in the repeated-dose study, which reversed after a two-week withdrawal period (Xu et al., 2020).

The second is a pharmacokinetic study in rats and beagle dogs. The elimination half-life of intact BPC-157 was under 30 minutes, kinetics were linear across the exposure levels tested, and tritium-labelled peptide was rapidly broken down into small peptide fragments and single amino acids, excreted mainly in urine and bile (He et al., 2022). This is the main published pharmacokinetic data set for the compound, and it is in animals. It also sits uneasily beside the “stable” label: whatever the peptide’s resistance to gastric juice, the intact molecule did not persist long in the circulation of these animals.

Who has done most of the research?

A large share of the BPC-157 literature comes from one research group at the University of Zagreb School of Medicine, in its departments of pharmacology and pathology. The 1993 description, the tendon and muscle transection studies, the gastrointestinal work and the CNS series discussed above all carry authors from this group, and the group has also written many of the review articles on the compound.

This does not make the findings wrong, but it matters for how much weight they can carry. Findings repeated within one laboratory share its methods, models, peptide source and assessment practices; independent replication tests whether a finding survives a change in all of those. An independent review from Loughborough University in the UK noted that only a handful of research groups had studied the peptide in depth over two decades, and that most studies used small rodent models (Gwyer et al., 2019). Work from outside Zagreb does exist, including the Chang Gung University cell and angiogenesis studies and the Xi’an toxicology and pharmacokinetic studies, but it is smaller in volume and narrower in scope.

A further feature of the literature is that, according to Gwyer et al. (2019), the musculoskeletal studies they reviewed consistently reported positive findings. A field in which almost no negative findings appear is one where publication bias and the absence of independent replication are reasonable open questions.

What human data exist?

Very little, and none of it is controlled.

In the 2000s, the Zagreb group described BPC-157 under the codes PL-10, PLD-116 and PL 14736 as being in clinical trials for inflammatory bowel disease (Sikiric et al., 2006). The 2026 systematic review described below found no peer-reviewed report of those trials among the human studies it could include.

A systematic review registered with PROSPERO and published in 2026 searched Embase, PubMed, the Cochrane Library and ClinicalTrials.gov up to 1 June 2026 for human studies of BPC-157 for any indication (Poolton et al., 2026). It found three studies with 30 people in total, all three led by the same first author and published in the same journal:

• A retrospective chart review of knee-pain cases at one clinic, 2019–2020, with 16 people reached by telephone survey. Pain and its duration were self-rated; no validated instruments, imaging or control group were used (Lee and Padgett, 2021).
• A single-arm pilot study of 12 women with interstitial cystitis at a private clinic, with symptoms assessed by the Global Response Assessment questionnaire and no control group (Lee et al., 2024).
• A pilot safety study in two people, both of whom had received the peptide before, measuring vital signs and blood biomarkers of heart, liver, kidney and thyroid function and blood glucose over three days (Lee and Burgess, 2025).

The review rated all three as being of poor methodological quality and the overall certainty of the evidence as very low, citing serious risk of bias, indirectness and imprecision (Poolton et al., 2026). An earlier systematic review focused on orthopaedic sports medicine, with searches to June 2024, included 36 studies, of which 35 were preclinical and one was a human study (Vasireddi et al., 2025).

Two registry entries are also relevant. A phase I, randomised, quadruple-masked study in healthy volunteers (NCT02637284), sponsored by PharmaCotherapia d.o.o. and planned for an estimated 42 people with adverse events as the primary outcome, was registered in 2015. Its record was last updated in December 2015, its status is listed as unknown, and no outcome data have been posted. A randomised, double-blind, placebo-controlled phase 2 study in acute grade II hamstring strain (NCT07437547), with an estimated 120 people and co-primary endpoints of time to return to sport and MRI-assessed injury volume, was listed as recruiting when this article was written. A registry entry describes a study design, not findings.

What are the open questions?

• Independent replication. Most of the in-vivo findings, particularly in the gastrointestinal and CNS models, have not been reproduced by unrelated laboratories using their own peptide source and blinded assessment.
• Mechanism. Proposed mechanisms include the NO system, VEGFR2–Akt–eNOS signalling and FAK–paxillin activation. These come from different models and groups and have not been joined into a single account.
• The parent protein. The 40,000 relative-molecular-mass gastric protein from which the fragment was derived has had little independent characterisation, so whether BPC-157 reflects an endogenous physiological signal remains unsettled.
• Pharmacokinetics. Published data come from one study in rats and dogs. How a peptide with a half-life under 30 minutes in those animals relates to the effects reported in longer rodent models is unexplained.
• Human evidence. There are no published randomised controlled studies. The existing human reports are small, uncontrolled and rated very low in certainty.
• Material quality. Comparing findings across laboratories depends on knowing the identity and purity of the peptide each one used. Our guide to reading a peptide Certificate of Analysis covers what those data look like.

Summary

BPC-157 is a well-defined synthetic 15-amino-acid peptide whose identity is easy to state and to check. The literature on it is large but concentrated: mostly rats, mostly surgical or chemical injury models, and mostly one laboratory, with smaller independent contributions on cell signalling, angiogenesis, toxicology and pharmacokinetics. The human record consists of three small uncontrolled reports and a handful of registry entries. For a researcher, the honest position is that BPC-157 is an interesting tool compound in animal and cell models with substantial open questions about replication and mechanism.